Trial Profile
A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bococizumab (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms SPIRE-AI
- Sponsors Pfizer
- 17 Mar 2017 Results of a pooled analysis from SPIRE-HR, SPIRE-LDL, SPIRE-LDL, SPIRE-LL, SPIRE-SI and SPIRE-AI studies (n=4449), published in the New England Journal of Medicine.
- 01 Aug 2016 Rationale and design published in the American Heart Journal
- 03 May 2016 According to a Pfizer media release, the results of the SPIRE-AI trial are expected to be part of a potential regulatory filing for bococizumab.